NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has released a draft local coverage determination for Guardant Health's comprehensive liquid biopsy test Guardant360, proposing limited coverage for the test in patients with advanced non-small cell lung cancer.

According to the LCD, released under Palmetto's MolDx program, coverage for the test would be restricted to patients with cancers at stage IIIB or higher, and performed either at diagnosis or at progression.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.